IRVINE, Calif., March 6, 2024 /PRNewswire/ — Muse Microscopy, Inc., a wholly-owned subsidiary of Smart Health Diagnostics Company, is developing a slide-free diagnostic imaging platform designed to transform the patient’s experience by providing the ability to generate digital tissue images within minutes to send to the pathologist for an immediate read.

Larry Dentice, the President and Director of Muse Microscopy, Inc., will present on March 21 at 10:45 am, Track 3, at LSI USA ’24. The presentation will focus on the future of direct-to-digital imaging using our SmartPath MUSE Technology™ (SmartPath) instrument. As a leader in innovative MUSE technology, we aim to revolutionize patient and pathology experiences by generating high-quality direct-to-digital images in minutes. SmartPath stands to be the first MUSE-enabled technology imaging platform that will be used in the commercial markets for both veterinary and human health. Our eventual strategic vision is to advance healthcare as a preferred data provider for applications of AI.

For more information about the LSI USA ’24 event, including registration details, please visit official event website at Emerging Medtech Summit 2024 – Life Science Intelligence (lifesciencemarketresearch.com)

About Muse Microscopy, Inc.

Muse Microscopy, Inc. is a company that specializes in the application of Microscopy with Ultraviolet Surface Excitation (MUSE). We have developed a MUSE-enabled imaging system for diagnostic assistance in pathology, cytology, and research applications. Our commercial product, SmartPath MUSE Technology™ (SmartPath), is a slide-free direct-to-digital imaging platform that aims to transform the patient’s experience and provide healthcare professionals with quick diagnostic information through digital imaging. To learn more, you can visit their website at https://musemicroscopy.com/ or find them on social media platforms such as Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “termed,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.

Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.

SOURCE Muse Microscopy, Inc.